The market for gene therapy in the treatment space is booming. Gene therapy products are sitting at a critical juncture: from technological pipedream to the centrepiece of clinical treatment.
Structural biologists have an insatiable desire to discover the structure of proteins: for insight into how proteins work, and what that means for drug discovery.
The robustness, low cost and ease of production of monobodies and nanobodies make them attractive therapeutic candidates for COVID19. High stability solves the need for cold-chain storage, and offers other routes of administration such as aerosols, which could be attractive for respiratory diseases.
To gain entry into human cells, the SARS-CoV-2 virus uses a “spike” on its surface, that recognizes receptors on human cells. One approach to making a vaccine is to immunise healthy patients with DNA or mRNA that codes for the spike protein.